title: The Neuroprotection of Lysosomotropic Agents in Experimental Subarachnoid Hemorrhage Probably Involving the Apoptosis Pathway Triggering by Cathepsins via Chelating Intralysosomal Iron.
abstract: α-Lipoic acid-plus (LAP), an amine derivative of α-lipoic acid (LA), could protect cells against oxidant challenges via chelating intralysosomal iron. However, the application of LAP in experimental subarachnoid hemorrhage (SAH) is still not well known. This study was designed to evaluate the potential neuroprotection of LAP on the early brain injury (EBI) and the underlying mechanisms in a rat model of SAH. The SAH models were induced in Sprague-Dawley rats. LA and LAP were oral administration and lasted for 72 h once a day. The brain tissue samples were obtained for assay at 72 h after SAH. In experiment 1, we found that lysosome amounts in neurons decreased significantly in SAH group, and LAP (100 mg/kg) could stabilize lysosomal membrane markedly based on lysosomal-associated membrane protein-1 (LAMP-1) expression in neurons by immunofluorescence. Hence, the LAP dosages of 100 and 150 mg/kg were applied in experiment 2. Firstly, Western blot analysis showed that the protein levels of cathepsin B/D, caspase-3, Bax, ferritin, and heme-oxygenase-1 (HO-1) markedly increased after SAH, which were further confirmed by double immunofluorescence staining and reversed by LA and LAP treatments. In addition, LA and LAP also reduced oxidative stress and iron deposition in brain tissue. Furthermore, LA and LAP significantly ameliorated brain edema, blood-brain barrier injury, cortical apoptosis, and neurological behavior impairment induced by SAH. Finally, it is noteworthy that LAP exerted more significant effects than LA on these parameters as described above. LAP probably exerted neuroprotective effects via targeting lysosomes and chelating intralysosomal iron in EBI post-SAH in rats.
authors.affiliation: Department of Neurosurgery, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, People's Republic of China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Wang
authors.forename: Anju
authors.initials: A
authors.lastname: Gao
authors.forename: Xiang
authors.initials: X
authors.lastname: Xu
authors.forename: Baoqi
authors.initials: B
authors.lastname: Dang
authors.forename: Wanchun
authors.initials: W
authors.lastname: You
authors.forename: Haiying
authors.initials: H
authors.lastname: Li
authors.forename: Zhengquan
authors.initials: Z
authors.lastname: Yu
authors.forename: Gang
authors.initials: G
authors.lastname: Chen
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D001522:Behavior, Animal; D001812:Blood-Brain Barrier / Q000187:drug effects / Q000473:pathology; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D001929:Brain Edema / Q000150:complications / Q000473:pathology; D053148:Caspase 3 / Q000378:metabolism; D002403:Cathepsins / Q000378:metabolism*; D005293:Ferritins / Q000378:metabolism; D051547:Heme Oxygenase-1 / Q000378:metabolism; D007501:Iron / Q000378:metabolism*; D007502:Iron Chelating Agents / Q000494:pharmacology*; D008247:Lysosomes / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008954:Models, Biological; D000066829:Neuroprotection / Q000187:drug effects*; D018696:Neuroprotective Agents / Q000737:chemistry / Q000494:pharmacology*; D018384:Oxidative Stress / Q000187:drug effects; D010539:Permeability; D017207:Rats, Sprague-Dawley; D013345:Subarachnoid Hemorrhage / Q000150:complications / Q000473:pathology*; D008063:Thioctic Acid / Q000494:pharmacology; D051028:bcl-2-Associated X Protein / Q000378:metabolism
chemical_list: D007502:Iron Chelating Agents; D018696:Neuroprotective Agents; D051028:bcl-2-Associated X Protein; D008063:Thioctic Acid; D005293:Ferritins; D007501:Iron; D051547:Heme Oxygenase-1; D002403:Cathepsins; D053148:Caspase 3
references.citation: Brain Res. 2011 Jan 25;1370:185-93
references.pmid: 21108937
references.citation: Redox Biol. 2013 Jan 30;1:80-5
references.pmid: 24024140
references.citation: J Biol Chem. 2009 Aug 14;284(33):21783-21787
references.pmid: 19473965
references.citation: Neurochem Res. 2002 Mar;27(3):237-42
references.pmid: 11958522
references.citation: Neuropathol Appl Neurobiol. 2014 Apr;40(3):270-83
references.pmid: 24117543
references.citation: Best Pract Res Clin Anaesthesiol. 2010 Dec;24(4):511-20
references.pmid: 21619863
references.citation: Biochim Biophys Acta. 2012 Jan;1824(1):22-33
references.pmid: 21914490
references.citation: Surg Neurol. 2001 Apr;55(4):197-203
references.pmid: 11358585
references.citation: Chem Biol Drug Des. 2014 Jun;83(6):688-96
references.pmid: 24417981
references.citation: J Neurotrauma. 2014 Mar 1;31(5):515-29
references.pmid: 24083575
references.citation: Pediatr Neurol. 2001 Aug;25(2):118-29
references.pmid: 11551742
references.citation: Mediators Inflamm. 2013;2013:187873
references.pmid: 24282339
references.citation: Acta Neurochir Suppl. 2011;111:133-7
references.pmid: 21725744
references.citation: Free Radic Biol Med. 2003 May 15;34(10):1243-52
references.pmid: 12726912
references.citation: Neurol Sci. 2013 Jul;34(7):1173-80
references.pmid: 23079850
references.citation: Neurosci Lett. 2012 Mar 14;512(1):6-11
references.pmid: 22306092
references.citation: Neurochem Res. 2010 Mar;35(3):418-28
references.pmid: 19823933
references.citation: Antioxid Redox Signal. 2013 Mar 10;18(8):888-98
references.pmid: 22909065
references.citation: J Cereb Blood Flow Metab. 2003 Jun;23(6):629-52
references.pmid: 12796711
references.citation: Free Radic Biol Med. 2003 May 15;34(10):1295-305
references.pmid: 12726917
references.citation: Neurol Res. 2006 Jun;28(4):399-414
references.pmid: 16759443
references.citation: Free Radic Biol Med. 1999 Jun;26(11-12):1418-26
references.pmid: 10401605
references.citation: Biochem Pharmacol. 1991 May 1;41(9):1361-3
references.pmid: 2018567
references.citation: Neurosci Lett. 2013 Oct 25;554:121-5
references.pmid: 24035895
references.citation: Turk Neurosurg. 2011;21(4):527-33
references.pmid: 22194111
references.citation: Arch Biochem Biophys. 2007 Jun 15;462(2):220-30
references.pmid: 17306211
references.citation: Acta Neurochir Suppl. 2011;112:101-6
references.pmid: 21691996
references.citation: Acta Neurochir Suppl. 2011;110(Pt 1):43-8
references.pmid: 21116913
references.citation: Acta Neurochir Suppl. 2008;104:33-41
references.pmid: 18456995
references.citation: Int J Clin Exp Pathol. 2013 Jun 15;6(7):1294-305
references.pmid: 23826410
references.citation: J Pharm Pharmacol. 1999 Feb;51(2):131-4
references.pmid: 10217310
references.citation: FEBS Lett. 2011 Feb 18;585(4):623-9
references.pmid: 21219901
references.citation: PLoS One. 2014 Feb 14;9(2):e86407
references.pmid: 24551038
references.citation: ACS Nano. 2013 May 28;7(5):3939-52
references.pmid: 23634880
references.citation: Lancet Neurol. 2006 Jan;5(1):53-63
references.pmid: 16361023
references.citation: J Neurosurg. 2011 Apr;114(4):1110-6
references.pmid: 20672894
references.citation: J Cereb Blood Flow Metab. 2004 Aug;24(8):916-25
references.pmid: 15362722
references.citation: J Pineal Res. 2012 Sep;53(2):129-37
references.pmid: 22304528
references.citation: J Cereb Blood Flow Metab. 2010 Nov;30(11):1791-2
references.pmid: 20736954
references.citation: Turk Neurosurg. 2012;22(5):529-33
references.pmid: 23015327
references.citation: J Pineal Res. 2008 Mar;44(2):197-204
references.pmid: 18289172
references.citation: J Cereb Blood Flow Metab. 2010 Nov;30(11):1793-803
references.pmid: 20736956